Trial outcomes and results of dose comparisons
| . | DA60 . | DA90 . | OR/HR and CI . | P . |
|---|---|---|---|---|
| CR | 75% | 73% | 1.07 (0.83-1.39) | .6 |
| CRi | 9% | 8% | ||
| CR/CRi | 84% | 81% | 1.21 (0.90-1.63) | .2 |
| Induction death | 4% | 6% | 1.63 (0.97-2.73) | .07 |
| Resistant disease | 12% | 13% | 1.04 (0.74-1.47) | .8 |
| CR/CRi post–course 1 | 66% | 68% | 0.89 (0.70-1.14) | .4 |
| 30-day mortality | 4% | 6% | 1.56 (0.94-2.61) | .09 |
| 60-day mortality | 5% | 10% | 1.98 (1.30-3.02) | .001 |
| 2-year OS | 60% | 59% | 1.16 (0.95-1.43) | .15 |
| 2-year RFS | 48% | 51% | 1.05 (0.85-1.30) | .7 |
| 2-year cumulative incidence of relapse | 43% | 39% | 1.00 (0.79-1.27) | 1.0 |
| 2-year cumulative incidence of death in CR | 8% | 10% | 1.27 (0.79-2.04) | .3 |
| 2-year OS from CR | 69% | 70% | 1.04 (0.79-1.38) | .8 |
| 2-year OS censored at SCT | 60% | 60% | 1.20 (0.96-1.51) | .11 |
| . | DA60 . | DA90 . | OR/HR and CI . | P . |
|---|---|---|---|---|
| CR | 75% | 73% | 1.07 (0.83-1.39) | .6 |
| CRi | 9% | 8% | ||
| CR/CRi | 84% | 81% | 1.21 (0.90-1.63) | .2 |
| Induction death | 4% | 6% | 1.63 (0.97-2.73) | .07 |
| Resistant disease | 12% | 13% | 1.04 (0.74-1.47) | .8 |
| CR/CRi post–course 1 | 66% | 68% | 0.89 (0.70-1.14) | .4 |
| 30-day mortality | 4% | 6% | 1.56 (0.94-2.61) | .09 |
| 60-day mortality | 5% | 10% | 1.98 (1.30-3.02) | .001 |
| 2-year OS | 60% | 59% | 1.16 (0.95-1.43) | .15 |
| 2-year RFS | 48% | 51% | 1.05 (0.85-1.30) | .7 |
| 2-year cumulative incidence of relapse | 43% | 39% | 1.00 (0.79-1.27) | 1.0 |
| 2-year cumulative incidence of death in CR | 8% | 10% | 1.27 (0.79-2.04) | .3 |
| 2-year OS from CR | 69% | 70% | 1.04 (0.79-1.38) | .8 |
| 2-year OS censored at SCT | 60% | 60% | 1.20 (0.96-1.51) | .11 |
RFS, relapse-free survival; SCT, stem cell transplant.